CYCN News and Press, Cyclerion Therapeutics Inc. From 04/24/21

Are These On Your List Of Penny Stocks To Buy Right Now? Everyone knows penny stocks can be risky. But with that higher risk comes the potential for higher rewards. Sure penny stocks under $0.50 that jump a quarter or more bring some big wins and great excitement to traders. How about t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Cheryl Gault, Chief Operating Officer will present a corporat...

Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS Neuropsychiatric key opinion leader, Andreas Reif, M.D. to discuss role of sGC pathway in CIAS Webcast scheduled for Tuesday, ...

Are These The Best Penny Stocks To Buy Right Now? There’s no doubt that penny stocks present an interesting option for traders. By definition, we’re talking about companies with shares trading below $5 and are well-known for their higher level of risk. Even with this as th...

Cyclerion Therapeutics (CYCN) announces that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has resigned his position with the company. He will provide with transitional support until March 26, 2021 and will join the company’s Clinical Advisory Board. For further d...

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Christopher Wright, M.D., Ph.D., Chief Medical Officer, has r...

Cyclerion Therapeutics (CYCN): FY net loss of 77.8M.Cash, cash equivalents, and restricted cash balance on December 31, 2020 was approximately $58 million, as compared to approximately $71 million on September 30, 2020.Press Release For further details see...

Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers associated with cognitive impairment, including neuroinflammatory biomarkers; MELAS P...

ATA Creativity Global AACG -41% pared down yesterday's gain as Reddit users pump.Document Security Systems DSS -32% after pricing equity offering.Midatech Pharma (MTP) -21%.Twist Bioscience TWST -17% after JPMorgan downgrade.FirstMark Horizon Acquisition (FMAC) -...